1yr
Share
1yr
Diet and Lipid-Lowering Nutraceuticals in Pediatric Patients with Familial Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38397362/
Familial hypercholesterolemia is a genetically determined disease characterized by elevated plasma total and LDL cholesterol levels from the very first years of life, leading to early atherosclerosis. Nutritional intervention is...
This review examines nutritional interventions and nutraceuticals for treating dyslipidemia in childhood, focusing on lipid-lowering supplements, their mechanisms, and the benefits and risks in pediatric patients with severe dyslipidemia.
Share
1yr
Familial hypercholesterolemia in children and the importance of early treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38363694/
Children with familial hypercholesterolemia benefit from early detection and optimal treatment of their elevated LDL-C levels.
Early detection and optimal lipid-lowering therapy in children with familial hypercholesterolemia reduce the risk of premature atherosclerotic cardiovascular disease, with novel treatments improving outcomes and cost-effectiveness.
Share
1yr
Austria's health technology assessment (HTA) practices underutilize economic evaluations despite rising healthcare costs. This commentary proposes broadening methods beyond cost-effectiveness analysis to reflect diverse values and address high-cost technologies. Innovative approaches may enhance HTA relevance in Austria and globally.
Share
1yr
Did you know? The World Health Organization (WHO) considers an intervention cost-effective if it costs three times a person’s income per quality-adjusted life year (QALY) gained. In the U.S., with an average income of around $40,000, this means interventions costing less than $120,000 per QALY are deemed cost-effective. Harvard economist David Cutler suggests $100,000 as a reasonable benchmark.
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
.png)
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
Share